Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

CRISPR–Cas-related technologies in basic and translational liver research

Nature Reviews Gastroenterology & Hepatology volume 15, pages 251–252 (2018)Cite this article

Subjects

CRISPR–Cas9 has revolutionized biomedical research. Studies in the past few years have achieved notable successes in hepatology, such as correction of genetic disease genes and generation of liver cancer animal models. Where does this technology stand at the frontier of basic and translational liver research?

Introduction

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Figure 1: New CRISPR-Cas9-based technologies.

References

  1. Doudna, J. A. & Charpentier, E. The new frontier of genome engineering with CRISPR-Cas9. Science 346, 1258096 (2014).

    Article  PubMed  Google Scholar 

  2. Pankowicz, F. P. et al. CRISPR/Cas9: at the cutting edge of hepatology. Gut 66, 1329–1340 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Hess, G. T. et al. Methods and applications of CRISPR-mediated base editing in eukaryotic genomes. Mol. Cell 68, 26–43 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Yin, H. et al. Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing. Nat. Biotechnol. 35, 1179–1187 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Sanchez-Rivera, F. J. & Jacks, T. Applications of the CRISPR-Cas9 system in cancer biology. Nat. Rev. Cancer 15, 387–395 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Song, C. Q. et al. Genome-wide CRISPR screen identifies regulators of mitogen-activated protein kinase as suppressors of liver tumors in mice. Gastroenterology 152, 1161–1173.e1 (2017).

    Article  CAS  PubMed  Google Scholar 

  7. Wang, D. et al. Adenovirus-mediated somatic genome editing of Pten by CRISPR/Cas9 in mouse liver in spite of Cas9-specific immune responses. Hum. Gene Ther. 26, 432–442 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Tsai, S. Q. et al. GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat. Biotechnol. 33, 187–197 (2014).

    Article  PubMed  PubMed Central  Google Scholar 

  9. Suzuki, K. et al. In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration. Nature 540, 144–149 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Abudayyeh, O. O. et al. RNA targeting with CRISPR-Cas13. Nature 550, 280–284 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

S.C.Q. is a postdoc and W.X. is an assistant professor at the RNA therapeutic Institute at UMass Medical School. The authors thank Y. Hao for critical comments and discussions and A. Sheel for proofreading. W.X. was supported by grants from the National Institutes of Health (DP2HL137167 and P01HL131471), American Cancer Society (129056-RSG-16-093), Lung Cancer Research Foundation, Hyundai Hope on Wheels and ALS Association.

Author information

Authors and Affiliations

  1. RNA Therapeutics Institute, University of Massachusetts Medical School,

    Chun-Qing Song & Wen Xue

  2. Department of Molecular, Cell and Cancer Biology and Program of Molecular Medicine, University of Massachusetts Medical School, Worcester, MA, USA

    Wen Xue

Authors
  1. Chun-Qing Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wen Xue
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wen Xue.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary information S1 (table)

Selected studies of CRISPR–Cas for somatic genome editing for liver disease and cancer. (PDF 100 kb)

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Song, CQ., Xue, W. CRISPR–Cas-related technologies in basic and translational liver research. Nat Rev Gastroenterol Hepatol 15, 251–252 (2018). https://doi.org/10.1038/nrgastro.2018.11

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrgastro.2018.11

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research